IMEXHS LIMITED — AGM Information 2022

May 18, 2022

==> picture [181 x 58] intentionally omitted <==

Annual General Meeting 19 May 2022

Board of Directors

==> picture [132 x 157] intentionally omitted <==

==> picture [131 x 157] intentionally omitted <==

==> picture [131 x 157] intentionally omitted <==

==> picture [132 x 157] intentionally omitted <==

Doug Flynn Carlos Palacio Dr Doug Lingard Damian Banks Dr German Arango Non-Executive Non-Executive Non-Executive Non-Executive CEO & Managing Chairman Director Director Director Director

IMEXHS LTD (ASX:IME) | AGM May 19 2022

2

==> picture [720 x 405] intentionally omitted <==

----- Start of picture text -----

Registration & Voting
2. Click view and register 3. Record your vote. Once
1. Log in or register at:
https://investor.automic.com.au/#/home your attendance for the you confirm it is lodged and
meeting final
To contact support:
Call 1300 816 159 or open live chat from the Investor Portal
----- End of picture text -----

Agenda 2022 AGM

==> picture [118 x 49] intentionally omitted <==

==> picture [382 x 169] intentionally omitted <==

1. Introductions

2. Chairman’s Address

3. CEO’s Address

4. Business of Meeting

5. Resolutions & Proxy Vote Results

4

==> picture [118 x 37] intentionally omitted <==

Chairman’s Address Doug Flynn

One Company with two businesses aimed at democratising access to medical expertise

==> picture [118 x 49] intentionally omitted <==

==> picture [118 x 37] intentionally omitted <==

CEO’s Address Dr German Arango

Our 10-year Journey

Founded in Bogota, Colombia to provide access to medical technology in 2012 hard-to-reach areas 2015 Expanded into countries in Latin America such as Ecuador and Mexico 2018 Listed on the Australian Securities Exchange to expand our global presence 2019 Received FDA Clearance in the US, expanded into new medical verticals & AI tools Launched a standardized radiology imaging solution, AQUILA Cloud, and 2020 expanded into the US Purchased RIMAB SAS to strengthen radiology services business to access vast 2021 amounts of data for AI development

8

Expanding global footprint

Software

15 countries; 398 sites

2,500+ radiologists

35 distributors in 17 countries

Services

Colombia, Spain and Mexico

33 radiology centres

100+ in-house radiologists

==> picture [118 x 50] intentionally omitted <==

37 software development engineers

9

==> picture [119 x 50] intentionally omitted <==

Annual Recurring Revenue (ARR)

Sales Revenue[1]

$13.4m

$20.4m

Up 102% yoy

Up 23% yoy

Up 121% on a constant currency basis

Up 34% on a constant currency basis

Recurring Closing cash revenue Up 43% yoy $12.2m Vs $10.8m at 31 $4.2m Up 57% on a constant December 2020 currency basis

EBITDA

($3.0m)

vs ($1.3m) in FY20

due to continued investment in operations

Underlying EBITDA[2] vs ($0.7m) in FY20 ($1.4m)

==> picture [74 x 23] intentionally omitted <==

– Enterprise Imaging – RIS, PACS, VNA Results Distribution Portal – – Digital Pathology – Interoperability – Teleradiology – Multi-Departmental

– Radiology Outsourcing – Diagnostic / Report – Teleradiology – Digital Pathology – ML/DL training, validation Academic Research –

Open collaborative platform

• Medical Imaging platform

• Cloud Technology

• Multitenant

• DevOps

• Onboarding automation

• SaaS / PaaS Business Model

• Lesion detection

• Image Quantification

• – Workflow optimization

• Clinical Triage

• Medical Decision Support

• Second Opinion

• Preliminary Diagnostic

5-year Strategy Framework

2025+ Harvesting 10% Resource Allocation

2024 | 2025 Growing (Product Offering) 20% Resource Allocation

IMEXHS Cloud

• Single Unified Medical Imaging Single Software Software Platform Platform

• • SaaS/PaaS architecture • Other ologies (Base + Extensions) Digital pathology

Medical Services

• 2022 | 2023 AI (Radiology + Pathology) Seeding • Dedicated team (Scale-Up) • Data Lake 70% Resource Allocation • Integrated engine • Algorithms development AI

• Growth Strategy for three business segments 1. IMEXHS Cloud SME Medical Imaging 2. IMEXHS Cloud Enterprise Radiology Services Services Platform 3. Radiology Services • International outsourcing & teleradiology services Partner of choice for:

• Based on four areas: powered by AI 1. Product – Unified Medical Imaging Platform •• Medical Imaging AppsPowered by AI 2. Sales – Dynamic Proactive Sales Team • Healthcare Services 3. Customer segmentation (Radiology, Pathology & 4. Geographic expansion others)

12

Current Trading

• Q1 FY22 revenue of $4.7m, up 89% vs pcp (88% on a constant currency basis) and up 39% excluding RIMAB

• Underlying Q1 FY22 EBITDA loss of $0.2m, up $0.6m vs pcp of loss of $0.8m

• Annual Recurring Revenue (ARR) of $21.5m, up 95% vs pcp (94% on a cc basis)

• IMEXHS Cloud (formerly AQUILA in the Cloud) 128 contracts signed year-to-date with ARR of $2.8m

• Signed 5 new partners from

• 3 different countries and signed 2 new Master Distributors - Crowd IT in Australia and 3verest in the UK

• Entered Thai market with FDA registration, a distribution agreement with BJC and an IMEXHS Cloud order

==> picture [118 x 49] intentionally omitted <==

13

Strong growth in ARR continues

==> picture [459 x 199] intentionally omitted <==

----- Start of picture text -----

Q1
20172018201920202021 FY22 +95% pcp (+94%
25 on a constant
currency basis)
20
15
10
5
0
2017 2018 2019 2020 2021 Q1 FY22
A$ Millions
----- End of picture text -----

Spot Not Yet Billing Constant Currency Not Yet Billing

ARR as at 31 March 2022

• $21.5m = $14.1m from Radiology Services and $7.4m from Software

• Includes $1.1m from Colombia’s National Police Central Hospital contract won in Dec-21

Constant currency basis assumes that historic results are converted at the average Q1 FY22 exchange rate. This removes the impact of changes in currency rates and allows comparison of IMEXHS’s underlying operating performance.

14

FY22 Outlook

Initiatives to reach profitability and cashflow breakeven while continuing to keep the integrity of our 5-year strategic framework

• Cost savings that minimise any impact on the operations and growth plans

• Focus on working capital

• Non-cash payments to Directors

Global expansion – fuelled by recent Neusoft Medical partnership, entry into Thailand and greater presence in the US, Australia and the UK

Updated FY22 guidance –

• Revenue between $19.5m to $22.0m (vs $13.4m in FY21)

• Underlying EBITDA positive for 2022 (vs loss of $1.4m in FY21)

• • Monthly run-rate underlying cash breakeven during 2H FY22

15

==> picture [118 x 37] intentionally omitted <==

Business of Meeting

==> picture [118 x 37] intentionally omitted <==

Resolutions & Proxy Vote Results

Financial Report

To receive the financial report of the Company and the reports of the Directors and of the Auditors for the financial year ended 31 December 2021.

Q&A

Resolution 1: Remuneration Report

“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration Report for the financial year ended 31 December 2021 as disclosed in the Company’s Annual Report be adopted.”

==> picture [318 x 158] intentionally omitted <==

----- Start of picture text -----

Proxy votes
For Against Open
4,655,492 25,482 10,784
99.23% 0.54% 0.23%
----- End of picture text -----

Resolution 2: Re-election of Director

“That, for the purpose of Article 6.3(c) of the Constitution, ASX Listing Rule 14.5, and for all other purposes, Mr Carlos Palacio, a Director, retires by rotation, and being eligible, is re-elected as a Director of the Company.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
8,267,963 10,189 21,562
99.62% 0.12% 0.26%
----- End of picture text -----

Resolution 3: Grant of Options to the Chief Executive Officer

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 73,393 Options to the Managing Director & CEO, Dr German Arango, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,648,083 33,838 10,784
99.05% 0.72% 0.23%
----- End of picture text -----

Resolution 4: Grant of Options to Non-Executive Director Mr Damian Banks

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 20,044 Options to Non-Executive Director, Mr Damian Banks, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,648,083 33,838 10,784
99.05% 0.72% 0.23%
----- End of picture text -----

Resolution 5: Grant of Options to Non-Executive Director Mr Douglas Flynn

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 40,087 Options to Non-Executive Director, Mr Douglas Flynn, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 133] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,648,083 33,838 10,784
99.05% 0.72% 0.23%
----- End of picture text -----

Resolution 6: Grant of Options to Non-Executive Director Dr Doug Lingard

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 20,044 Options to Non-Executive Director, Dr Doug Lingard, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,602,290 79,631 10,784
98.07% 1.70% 0.23%
----- End of picture text -----

Resolution 7: Grant of Options to Non-Executive Director Mr Carlos Palacio

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the grant of 20,044 Options to Non-Executive Director, Mr Carlos Palacio, under the Plan on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

==> picture [318 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,648,083 33,838 10,784
99.05% 0.72% 0.23%
----- End of picture text -----

Resolution 8: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Damian Banks

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Mr Damian Banks, in lieu of the payment of certain director fees payable to Mr Damian Banks under the Plan and on the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

For	Against	Open
4,658,797	20,968	10,784
99.32%	0.45%	0.23%

Resolution 9: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Douglas Flynn

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Mr Douglas Flynn, in lieu of the payment of certain director fees payable to Mr Douglas Flynn, under the Plan and non the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

For	Against	Open
4,658,797	20,968	10,784
99.32%	0.45%	0.23%

Resolution 10: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Dr Doug Lingard

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Dr Doug Lingard, in lieu of the payment of certain director fees payable to Dr Doug Lingard, under the Plan and on the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

==> picture [319 x 132] intentionally omitted <==

----- Start of picture text -----

For Against Open
4,658,797 20,968 10,784
99.32% 0.45% 0.23%
----- End of picture text -----

Resolution 11: Issue of Shares in Lieu of Payment of Non-Executive Director Fees to Carlos Palacio

“That, for the purposes of ASX Listing Rule 10.14 and all other purposes, the Shareholders approve the issue of Shares to the Non-Executive Director, Mr Carlos Palacio, in lieu of the payment of certain director fees payable to Mr Carlos Palacio, under the Plan and the terms and conditions set out in the Explanatory Statement, with the number of Shares to be calculated in accordance with the formula set out in the Explanatory Statement.”

Proxy votes

For	Against	Open
4,658,797	20,968	10,784
99.32%	0.45%	0.23%

Resolution 12: Approval of 10% Share Placement Capacity

"That, for the purposes of ASX Listing Rule 7.1A and for all other purposes, Shareholders approve the Company having additional capacity to issue Equity Securities up to 10% of the issued capital of the Company (at the time of the issue) ( 10% Share Placement Capacity ) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions set out in the Explanatory Statement.”

Proxy votes

For	Against	Open
8,266,449	25,190	10,784
99.57%	0.30%	0.13%

Disclaimer

The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and conditions set out in this notice.

The Recipient should not treat the Information as advice relating to legal, taxation, financial product or investment matters and should consult their own advisers. This Presentation does not purport to contain all the information that a prospective investor may require. The Information may not be appropriate for all persons and it is not possible for ImExHS Limited to have regard to the investment objectives, financial situation and particular needs of each Recipient who reads or uses the Information. Accordingly, no recommendation or expression of opinion is contained within the Information. Further, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the Information, including the likelihood of achievement or reasonableness or any forecasts, prospects or returns contained in the Information. Before acting in reliance on any Information, the Recipient should conduct their own investigation and analysis in relation to the investment opportunity presented by this Presentation and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers.

Statements contained in the Information, particularly those regarding possible or assumed future performance or potential growth, prospects or projections of ImExHS Limited are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks, uncertainties and contingencies. The Information may also be subject to clarification and change and ImExHS Limited may in its absolute discretion, but without being under any obligation to do so, update, amend or supplement the Information.

The Information is for informational purposes only and does not constitute an offer to issue, or arrange to issue, securities or other financial products. The Information is not, and should not be construed to be, a Prospectus.

To the maximum extent permitted by law none of ImExHS Limited or its respective employees, agents or consultants nor any other person accepts any liability, including, without limitation, any liability arising out of fault of negligence, for any loss arising from the use of the Information.

31

Annual General Meeting 19 May 2022